High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy

Cancer

Volumn 82, Issue 9, 1998, Pages 1626-1631

  Yeh, Kun Huei ^a,b   Shun, Chia Tung ^a   Chen, Chi Long ^a   Lin, Jaw Town ^a   Lee, Wei Jei ^a   Lee, Po Huang ^a   Chen, Yao Chang ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

5 Fluorouracil; Drug resistance; Gastric carcinoma; Thymidylate synthase

Indexed keywords

FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; THYMIDYLATE SYNTHASE;

EID: 0032080712     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8     Document Type: Article

References (33)

1. Boeing H. Epidemiological research in stomach cancer: progress over the last ten years. J Can Res Clin Oncol 1991;117:133-43.
2. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
3. Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, McArdle CS. An evaluation of the prognostic factors in gastric cancer : the effects of chemotherapy on survival. Br J Surg 1987;74:715-21.
4. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:257-77.
5. Wilke H, Preusser P, Fink U, Achterrath W, Meyer H-J, Stahl M, et al. New development in the treatment of gastric carcinoma. Semin Oncol 1990;17(1 Suppl. 2):61-70.
6. Yeh KH, Cheng AL, Chen YC, Chen BR, Lee WJ, Lin JT, et al. Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study. J Formos Med Assoc 1994;93:20-4.
7. Cheng AL, Yeh KH, Chen YC, Lin JT, Chen BR, Liu MY, et al. PE-HDFL: an effective combination chemotherapy for advanced gastric cancers [abstract 1582]. Proc Am Soc Clin Oncol 1996;15:495.
8. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, et al. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: an effective and low-toxic regimen for patients with poor general condition. Oncology 1997;54:275-80.
9. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
10. Rougier PH, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S. Oliverira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: a phase II trial with prognostic factor analysis. Eur J Cancer 1994;30A:1263-9.
11. Kelson D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
12. Robey-Cafferty SS, Ajani JA, Ota DM, Roth JA, Bruner JM. Histologic observations and p-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. Arch Pathol Lab Med 1991; 115:807-12.
13. Wallner J, Depisch D, Gsur A, Gotzl M, Haider K, Pirker R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 1993;71:667-71.
14. Peters GJ, van der Wilt CL, van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994;12:2035-42.
15. Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T, Sakaue M. Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 1992;70:2761-5.
16. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 1991;51:6668-76.
17. Johnston PG, Drake JC, Trepel I, Allegra CJ. Immunological quantitation of thymidylate synthase using monoclonal antibody TS106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992;52:4306-12.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
19. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
21. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient (Part II). Br J Cancer 1977;35:1-39.
22. Estimating and comparing means. In: Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. London: Appleton & Lange, Inc., 1994:99-124.
23. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
24. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
25. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986;4:685-96.
26. Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, et al. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer: a Southwest Oncology Group study. Cancer 1995;76:715-9.
27. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-12.
28. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, et al. Thymidylate synthase mRNA level in adeno-carcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
29. Barbour KW, Berger SH, Berger FG. Single amino acid substitution defines a naturally occuring genetic variant of human thymidylate synthase. Mol Pharmacol 1990;37:515-8.
30. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 1993;85:632-9.
31. Westwick JK, Bielawska AE, Dbaibo G, Hannun VA, Brenner DA. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995;270:22689-92.
32. Jarvis WD, Grant S, Kolesnick RN. Ceramide and induction of apoptosis. Clin Cancer Res 1996;2:1-6.
33. Wang CY, Mayo MW, Baldwin AS. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-erκB. Science 1996;274:784-7.